NICE approves Kuvan treatment for pregnant women

Pharmaceutical

NICE (The National Institute for Health and Care Excellence) has distributed a concluding advisory draft acclaiming BioMarin's Kuvan (sapropterin) as a choice for treating phenylketonuria (PKU) in pregnant women up to the point at which they give birth and for medicating the illness in individuals before age 22.

PKU is a lasting and persisting metabolic disorder triggered by the shortage of a particular enzyme that breaks down phenylalanine, which is presently treated through a protein-restricted diet that continues throughout their life.

“The board recognised that Kuvan might help avoid lasting, permanent brain damage in kids because childhood is the most crucial time for brain growth“

A public conference discussed NICE's prior draft advice, stating that Kuvan should only be used for treating children, so not being available once the patient reaches 18 years of age. The group decided that PKU is a big worry if it isn't precisely controlled during gestation. This is because it can cause serious hereditary defects in unborn babies.

NICE has now sanctioned women to take Kuvan sooner in their prenatal period because it has possibly improved their unborn children. The board recognised that Kuvan might help avoid lasting, permanent brain damage in kids because childhood is the most crucial time for brain growth.

Kuvan is currently suggested for individuals from 18 to 22 years of age to cover brain development and shift into maturity. Because the medication is weight-based dosing and has reservations concerning its effectiveness, the cost evaluations are more than that which NICE regards a suitable use of NHS funds for people over 22.

See all the latest jobs in Pharmaceutical
Return to news